← All trials
NCT04684719
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 30, 2022
- Primary completion
- Jul 31, 2025
- Completion date
- Sep 30, 2025
- First posted
- Dec 24, 2020
- Last posted
- Jul 2, 2021
- Enrollment
- 1020
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of PittsburghLead sponsor
- University of PittsburghSponsor investigator
- University of PittsburghOverall official - principal investigator
- Department of DefenseCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.